Trial Profile
A Multi-centre, Multinational, Open-label, Single-dose Acute Hemodynamic Study Followed by Multi-centre, Multinational, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy (Proof-of-concept) of ACT-293987 (NS-304) in the Treatment of Pulmonary Arterial Hypertension in Subjects Aged 18 Years and Over
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacodynamics; Proof of concept; Therapeutic Use
- Sponsors Actelion Pharmaceuticals
- 11 Dec 2014 New trial record